View Item 

Show simple item record

Economic Analysis of Alvimopan—A Clarification and Commentary

dc.contributor.authorBell, Timothy J.en_US
dc.contributor.authorPoston, Sara A.en_US
dc.contributor.authorKraft, Michael D.en_US
dc.contributor.authorSenagore, Anthony J.en_US
dc.contributor.authorTechner, Leeen_US
dc.date.accessioned2013-06-18T18:33:14Z
dc.date.available2014-07-01T15:53:23Zen_US
dc.date.issued2013-05en_US
dc.identifier.citationBell, Timothy J.; Poston, Sara A.; Kraft, Michael D.; Senagore, Anthony J.; Techner, Lee (2013). "Economic Analysis of Alvimopan—A Clarification and Commentary." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 33(5): e81-e82. <http://hdl.handle.net/2027.42/98345>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/98345
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherGastroenterologyen_US
dc.subject.otherSurgery Outcomesen_US
dc.subject.otherIleusen_US
dc.subject.otherAlvimopanen_US
dc.titleEconomic Analysis of Alvimopan—A Clarification and Commentaryen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid23065817en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/98345/1/phar1193.pdf
dc.identifier.doi10.1002/phar.1193en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceTouchette DR, Yang Y, Tiryaki F, Galanter WL. Economic analysis of alvimopan for prevention and management of postoperative ileus. Pharmacotherapy 2012; 32 ( 2 ): 120 – 8.en_US
dc.identifier.citedreferenceBell TJ, Poston SA, Kraft MD, Senagore AJ, Delaney CP, Techner L. Economic analysis of alvimopan in North American phase III efficacy trials. Am J Health Syst Pharm 2009; 66: 1362 – 8.en_US
dc.identifier.citedreferenceLudwig K, Enker WE, Delaney CP, et al. Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway. Arch Surg 2008; 143: 1098 – 105.en_US
dc.identifier.citedreferenceDelaney CP, Weese JL, Hyman NH, et al. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum 2005; 48: 1114 – 25; discussion 1125–6; author reply 1127–9.en_US
dc.identifier.citedreferenceViscusi ER, Goldstein S, Witkowski T, et al. Alvimopan, a peripherally acting mu‐opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double‐blind, controlled study. Surg Endosc 2006; 20: 64 – 70.en_US
dc.identifier.citedreferenceAbsher RK, Gerkin TM, Banares LW. Alvimopan use in laparoscopic and open bowel resections: initial clinical results in a large community hospital system. Ann Pharmacother 2010; 44: 1701 – 8.en_US
dc.identifier.citedreferenceWolff BG, Michelassi F, Gerkin TM, et al. Alvimopan, a novel, peripherally acting [mu] opioid antagonist: results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg 2004; 240: 728 – 34, discussion 734–5.en_US
dc.identifier.citedreferencePoston S, Broder MS, Gibbons MM, et al. Impact of alvimopan (Entereg) on hospital costs after bowel resection: results from a large inpatient database. P & T 2011; 36: 209 – 20.en_US
dc.identifier.citedreferenceDelaney CP, Craver C, Gibbons MM, et al. Evaluation of clinical outcomes with alvimopan in clinical practice: a national matched‐cohort study in patients undergoing bowel resection. Ann Surg 2012; 255: 731 – 8.en_US
dc.identifier.citedreferenceBüchler MW, Seiler CM, Monson JRT, et al. Clinical trial: alvimopan for the management of post‐operative ileus after abdominal surgery: results of an international randomized, double‐blind, multicentre, placebo‐controlled clinical study. Aliment Pharmacol Ther 2008; 28: 312 – 25.en_US
dc.identifier.citedreferenceAdolor Corporation. Entereg (alvimopan) capsules for postoperative ileus (POI), FDA advisory panel briefing document, 14 December 2007. Available from http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4336b1-02-Adolor.pdf. Accessed May 4, 2012.en_US
dc.identifier.citedreferenceWolff BG, Weese JL, Ludwig KA, et al. Postoperative ileus–related morbidity profile in patients treated with alvimopan after bowel resection. J Am Coll Surg 2007; 204: 609 – 16.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phar1193.pdf
Size:
26.60KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.